Next Generation PEGylation Technology

Downstream-MtViewPharm
Decreases in the immunoreactivity of next generation PEGylated drugs may be attainable by the use of monofunctionally activated hydroxyPEGs instead of methoxyPEGs in their synthesis.
Speaker:
Merry Sherman, President & Chief Executive Officer, Mountain View Pharmaceuticals

 

Listen to the audio cast here

Leave a Reply